$HYPR earnings report

Hyperfine reports record Q3 2026 revenue of $5,960 thousand (up 73% year over year), record gross margin of 57%, and a narrower operating loss; full-year 2026 revenue and net cash burn guidance continued. AlphAI read Hyperfine's Q3 FY2026 filing as solid. 2 quarters are on record below.

Q3 FY2026

AlphAI · Earnings readHYPR · Q3 2026 · ended 2026-09-30

Hyperfine reports record Q3 2026 revenue of $5,960 thousand (up 73% year over year), record gross margin of 57%, and a narrower operating loss; full-year 2026 revenue and net cash burn guidance continued

✓Solid quarter

Revenue grew 73% year over year, gross profit grew 83% (as printed), and the operating loss and net cash burn both narrowed. The company describes the quarter as a record for revenue, gross profit and gross margin. Offsetting this, the company still posted a GAAP net loss of $5,981 thousand, cash fell from $43.5 million at June 30, 2026 to $37.9 million at September 30, 2026 with no financing proceeds in the quarter, and long-term debt of $13,352 thousand now appears on the balance sheet.

Revenue
$5.96M
73% y/y · 53% q/q
Device sales (Q3 2026)
$5.24M
Gross margin · GAAP
57%
FY2026 outlook
approximately $20 to $22 million (company states 55% growth at the midpoint compared with full year 2025; the press release gives no FY2025 revenue figure)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total sales, Q3 2026 (three months ended Sep 30, 2026)GAAP$5.96M53%73%
Device sales, Q3 2026GAAP$5.24M––
Service sales, Q3 2026GAAP$717K––
Commercial Swoop systems sold, Q3 2026 (units)other14–75%
Cost of sales, total, Q3 2026GAAP$2.58M––
Cost of sales, device, Q3 2026GAAP$2.29M––
Cost of sales, service, Q3 2026GAAP$288K––
Gross profit, Q3 2026GAAP$3.38M–83%
Gross margin, Q3 2026GAAP57%––
Research and development expenses, Q3 2026GAAP$3.91M–decreasing 3%
General and administrative expenses, Q3 2026GAAP$4.05M––
Sales and marketing expenses, Q3 2026GAAP$2.67M––
Sales, marketing, general and administrative expenses, Q3 2026 (as stated in release text)GAAP$6.7M–relatively flat
Total operating expenses, Q3 2026GAAP$10.64M–decreased 1%
Loss from operations, Q3 2026GAAP−$7.26M–improvement of 19%
Interest income, Q3 2026GAAP$291K––
Interest expense, Q3 2026GAAP−$549K––
Change in fair value of warrant liabilities, Q3 2026GAAP$1.52M––
Other income (expense), net, Q3 2026GAAP$18K––
Loss before provision for income taxes, Q3 2026GAAP−$5.98M––
Net loss, Q3 2026GAAP−$5.98M––
Net loss per common share, basic and diluted, Q3 2026GAAP$(0.06)––
Net cash burn, Q3 2026non-GAAP$5.6M––
Total sales, nine months 2026 (nine months ended Sep 30, 2026)GAAP$13.77M––
Device sales, nine months 2026GAAP$11.67M––
Service sales, nine months 2026GAAP$2.10M––
Cost of sales, total, nine months 2026GAAP$6.43M––
Gross profit, nine months 2026GAAP$7.34M––
Research and development expenses, nine months 2026GAAP$11.62M––
General and administrative expenses, nine months 2026GAAP$12.09M––
Sales and marketing expenses, nine months 2026GAAP$7.91M––
Total operating expenses, nine months 2026GAAP$31.63M––
Loss from operations, nine months 2026GAAP−$24.28M––
Interest income, nine months 2026GAAP$817K––
Interest expense, nine months 2026GAAP−$1.17M––
Change in fair value of warrant liabilities, nine months 2026GAAP$704K––
Other income (expense), net, nine months 2026GAAP$26K––
Loss before provision for income taxes, nine months 2026GAAP−$23.90M––
Net loss, nine months 2026GAAP−$23.90M––
Net loss per common share, basic and diluted, nine months 2026GAAP$(0.24)––
Net cash used in operating activities, nine months 2026GAAP−$22.36M––
Net cash used in investing activities, nine months 2026GAAP−$293K––
Net cash provided by financing activities, nine months 2026GAAP$25.26M––
Net increase (decrease) in cash, cash equivalents and restricted cash, nine months 2026GAAP$2.61M––
Net financing proceeds, nine months 2026 (non-GAAP net cash burn input, as stated in footnote)non-GAAP$25M––

Segments

SegmentRevenueq/qy/y
Device sales (Q3 2026)Device sales of $5,243 thousand in Q3 2026 versus $2,891 thousand in Q3 2025. The filing prints no explanation for the device line specifically; the company's general commentary attributes the record revenue to the business as a whole.$5.24M––
Service sales (Q3 2026)Service sales of $717 thousand in Q3 2026 versus $546 thousand in Q3 2025. The filing prints no explanation for this line.$717K––
Device sales (nine months 2026)Device sales of $11,670 thousand for the nine months ended Sep 30, 2026 versus $6,541 thousand for the nine months ended Sep 30, 2025. No explanation printed.$11.67M––
Service sales (nine months 2026)Service sales of $2,097 thousand for the nine months ended Sep 30, 2026 versus $1,729 thousand for the nine months ended Sep 30, 2025. No explanation printed.$2.10M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

FY2026 outlook

  • Revenueapproximately $20 to $22 million (company states 55% growth at the midpoint compared with full year 2025; the press release gives no FY2025 revenue figure)
  • NoteNet cash burn (non-GAAP): approximately $26 to $28 million, representing a 10% decline at the midpoint as compared to full year 2025
  • NoteCompany states it continues to expect the revenue and net cash burn figures above (guidance wording in the release: 'continues to expect')
  • NoteNo reconciliation of full-year 2026 net cash burn guidance to GAAP net change in cash is provided; the company says future financing proceeds cannot be predicted without unreasonable efforts

Capital returns

  • No share repurchases or dividends are printed in the filing.
  • Net financing proceeds were $0.0 million for the quarter ended Sep 30, 2026, $10.6 million for the quarter ended Jun 30, 2026, and $2.1 million for the quarter ended Sep 30, 2025 (as stated in footnote 1).
  • Net financing proceeds in aggregate were $25.0 million for the nine months ended Sep 30, 2026 and $8.1 million for the nine months ended Sep 30, 2025.
  • Cash flow statement, nine months 2026: proceeds from issuance of debt, net $13,626 thousand; proceeds from at-the-market offering program, net $11,375 thousand; proceeds from exercise of stock options $259 thousand.
  • Cash flow statement, nine months 2025: proceeds from at-the-market offering program, net $2,906 thousand; proceeds from February 2025 offering with warrants, net $5,184 thousand; proceeds from exercise of stock options $130 thousand.
  • The company expects to file a new Form S-3 universal shelf registration to replace its existing shelf expiring in November 2026, registering an aggregate offering amount of $150 million, including a $50 million at-the-market offering program prospectus supplement, consistent with the existing registration statement.

What drove it

  • Company's explanation for the operating improvement: the release states that revenue grew 73% and gross profit grew 83% while total operating expenses decreased 1%, 'reflecting the operating leverage of the business.'
  • Gross margin of 57% in Q3 2026 versus 54% in Q3 2025, which the release describes as a record third-quarter gross margin. The filing does not state the cause of the margin change.
  • The net loss of $5,981 thousand includes a $1,516 thousand gain from a change in the fair value of warrant liabilities, compared with a $2,303 thousand loss in Q3 2025, as printed in the statement of operations.
  • Interest expense of $(549) thousand in Q3 2026 (nil printed for Q3 2025) appears alongside a balance sheet long-term debt line of $13,352 thousand.
  • Commercial system unit sales rose to 14 in Q3 2026 from 8 in Q3 2025 (75%, as printed).
  • Product and regulatory milestones cited by the company: Contrast PMR study enrollment completed; Swoop Model 2 launched in Europe and the UK with sales into four international markets; exclusive distributor agreement for Kuwait and the United Arab Emirates; Optive AI software clearance and CE/UKCA marking.

Concerns

  • Cash and cash equivalents fell from $43.5 million at Jun 30, 2026 to $37.9 million at Sep 30, 2026, and the company reports no net financing proceeds in Q3 2026.
  • GAAP net loss remained $(5,981) thousand in Q3 2026 and $(23,902) thousand for nine months 2026; the filing reports no GAAP profit.
  • Full-year 2026 net cash burn guidance of $26 to $28 million is non-GAAP and excludes financing; the company has not reconciled it to GAAP, and states that future financing proceeds could cause actual net change in cash to differ materially.
  • Long-term debt of $13,352 thousand is newly on the balance sheet, with interest expense of $(549) thousand in Q3 2026 and $(1,165) thousand for nine months 2026.
  • Total liabilities rose to $26,049 thousand from $14,257 thousand at Dec 31, 2025, and stockholders' equity fell to $31,744 thousand from $41,005 thousand.
  • The existing shelf registration is scheduled to expire in November 2026; the company expects to file a replacement, which signals a future need to access capital markets.
  • Accounts payable declined to $1,692 thousand from $4,051 thousand at Dec 31, 2025, while accrued expenses rose to $6,317 thousand from $5,130 thousand.
  • Gross profit, operating loss and net cash burn comparisons rely on the company's own release text for percentage changes; several line items in the statements carry no printed year-over-year percentage.

What to watch

  • Whether full-year 2026 revenue of approximately $20 to $22 million is reached, given nine-month total sales of $13,767 thousand printed in the filing.
  • FDA submission for the Contrast PMR study, which the company expects by the end of 2026.
  • Filing of the new Form S-3 shelf registration of $150 million, including the $50 million at-the-market program, before the existing shelf expires in November 2026.
  • Net cash burn trajectory versus the $26 to $28 million full-year guidance, and whether financing proceeds are needed for the remainder of 2026.
  • Sustainability of the 57% gross margin and the device and service revenue mix in coming quarters.
  • Interest expense and debt servicing following the March 2026 debt financing.
  • Commercial traction in Europe, the UK and the newly signed Kuwait and UAE distributor markets.

Balance sheet and cash flow

  • Cash and cash equivalents: $37,872 thousand at Sep 30, 2026 versus $35,085 thousand at Dec 31, 2025 (GAAP). Footnote 1 also states $40.8 million at Mar 31, 2026, $43.5 million at Jun 30, 2026, $25.4 million at Jun 30, 2025 and $21.6 million at Sep 30, 2025.
  • Restricted cash: $778 thousand at Sep 30, 2026 versus $957 thousand at Dec 31, 2025.
  • Total assets: $57,793 thousand at Sep 30, 2026 versus $55,262 thousand at Dec 31, 2025.
  • Total liabilities: $26,049 thousand at Sep 30, 2026 versus $14,257 thousand at Dec 31, 2025.
  • Long-term debt, net: $13,352 thousand at Sep 30, 2026 versus nil at Dec 31, 2025 (the balance sheet shows a dash for the prior period). The filing refers to a March 2026 debt financing and a Loan Agreement.
  • Warrant liabilities: $1,026 thousand at Sep 30, 2026 versus $1,730 thousand at Dec 31, 2025.
  • Total stockholders' equity: $31,744 thousand at Sep 30, 2026 versus $41,005 thousand at Dec 31, 2025.
  • Accumulated deficit: $(353,918) thousand at Sep 30, 2026 versus $(330,016) thousand at Dec 31, 2025.
  • Inventories: $6,378 thousand at Sep 30, 2026 versus $7,090 thousand at Dec 31, 2025.
  • Accounts payable: $1,692 thousand at Sep 30, 2026 versus $4,051 thousand at Dec 31, 2025.
  • Accrued expenses and other current liabilities: $6,317 thousand at Sep 30, 2026 versus $5,130 thousand at Dec 31, 2025.
  • Net cash used in operating activities for nine months 2026 was $(22,359) thousand, against $(22,741) thousand in nine months 2025. Purchases of property and equipment were $(293) thousand in nine months 2026 against $(1,122) thousand in nine months 2025.
  • Depreciation for nine months 2026 was $789 thousand; stock-based compensation expense was $2,512 thousand (nine months 2025: $809 thousand and $2,109 thousand).

Analysis

Hyperfine reported Q3 2026 total sales of $5,960 thousand, up 73% from $3,437 thousand in Q3 2025 and up 53% from the $3.9 million reported for Q2 2026. The company states that 14 commercial Swoop systems were sold in the quarter versus 8 a year earlier, and device sales were $5,243 thousand versus $2,891 thousand. Service sales were $717 thousand versus $546 thousand. For the nine months, total sales were $13,767 thousand against $8,270 thousand, with device sales of $11,670 thousand and service sales of $2,097 thousand. The filing does not break out the cause of the device or service growth beyond the company's general commentary.

Gross profit was $3,382 thousand, up from $1,848 thousand, and gross margin was 57% against 54% a year earlier. The company describes both as records. Cost of sales rose to $2,578 thousand from $1,589 thousand, with device cost of sales at $2,290 thousand versus $1,328 thousand. Operating expenses were broadly flat: R&D fell to $3,913 thousand from $4,048 thousand, G&A to $4,051 thousand from $4,152 thousand, and sales and marketing rose to $2,675 thousand from $2,568 thousand. Total operating expenses of $10,639 thousand were down 1% as printed. The company attributes the widening gap between revenue and costs to operating leverage. The loss from operations narrowed to $(7,257) thousand from $(8,920) thousand, an improvement of 19% as printed.

Below the operating line, the GAAP net loss was $(5,981) thousand, or $(0.06) per share, against $(11,019) thousand, or $(0.14) per share. The result includes a $1,516 thousand gain on warrant liabilities, compared with a $2,303 thousand loss a year earlier, and interest expense of $(549) thousand that had no comparable line in Q3 2025. The company reports non-GAAP net cash burn of $5.6 million, down from $5.9 million in Q3 2025 and $7.9 million in Q2 2026, and states that Q3 revenue exceeded net cash burn for the first time.

The balance sheet shows the funding pattern behind these figures. Cash fell to $37,872 thousand from $43,500,000 at June 30, 2026 (as printed in the footnote as $43.5 million), with net financing proceeds of $0.0 million in Q3 after $10.6 million in Q2. Long-term debt of $13,352 thousand is now on the balance sheet, against nil at December 31, 2025, and total liabilities rose to $26,049 thousand. Stockholders' equity fell to $31,744 thousand from $41,005 thousand, and the accumulated deficit reached $(353,918) thousand. Nine-month operating cash outflow was $(22,359) thousand, roughly unchanged from $(22,741) thousand a year earlier, and nine-month financing inflows were $25,260 thousand, including $13,626 thousand of debt proceeds and $11,375 thousand from the at-the-market program.

Full-year 2026 guidance was reiterated: revenue of approximately $20 to $22 million and non-GAAP net cash burn of approximately $26 to $28 million. The company states that these figures continue to be its expectations, and it does not provide a GAAP reconciliation for the burn guidance because future financing cannot be predicted. The company also expects to replace its shelf registration, which expires in November 2026, with a $150 million universal shelf. The figures that deserve the most attention are the cash decline in Q3 with no financing, the new debt and the interest expense it carries, and whether the full-year revenue range is met given the nine-month total in the filing.

Management, verbatim

Q3 2026 marked the beginning of a new trajectory for Hyperfine. We delivered record revenue, gross profit, and gross margin, and for the first time quarterly revenue exceeded net cash burn, demonstrating the operating leverage of our business.

Maria Sainz, President and Chief Executive Officer, Hyperfine, Inc.

Not in the filing

stated, not guessed
  • Q2 2026 total sales as an exact figure in thousands (only $3.9 million printed in the release text).
  • Q2 2026 full income statement, cost of sales, gross margin and operating expense lines.
  • Prior-year percentage changes for device sales, service sales, cost of sales lines, G&A, S&M, net loss, net loss per share and nine-month lines.
  • Gross margin change in percentage points year over year (only the 57% and 54% levels are printed).
  • Percentage change in net loss, interest income, interest expense and warrant fair value gains year over year.
  • FY2025 full-year revenue and net cash burn figures (the guidance percentages refer to full year 2025 but the base figures are not printed).
  • Prior-year net cash burn for the nine months and any nine-month net cash burn figure.
  • Prior guidance for comparison (no previous outlook was provided with this filing).
  • Gross margin, operating expense and tax rate guidance (not provided).
  • Reconciliation of full-year 2026 net cash burn guidance to GAAP net change in cash (company states it is not provided).
  • Explanation of the cause of device and service revenue growth, and of the gross margin change (not stated beyond general commentary).
  • Terms, interest rate and maturity of the March 2026 debt financing and Loan Agreement.
  • Share price reaction and analyst consensus (not in the documents).
  • Dec 31, 2025 comparison for cash: the Sep 30, 2025 balance sheet is not printed; cash of $21.6 million at Sep 30, 2025 appears only in the footnote.
  • Quarter-end cash balances for Q3 2025 cash flow line items (nine-month statement only).

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Third quarter 2026

AlphAI · Earnings readHYPR · Third quarter 2026 · ended September 30, 2026

Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million

✓Solid quarter

Preliminary third-quarter revenue is expected to reach approximately $6.0 million, up 53% sequentially, while preliminary net cash burn is expected to improve 29% sequentially to approximately $5.6 million. The company reaffirmed its full-year revenue and net cash burn outlook, although the results remain preliminary and unaudited.

Revenue
approximately $6.0 million
53% sequentially q/q
Full year 2026 outlook
approximately $20 to $22 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Third quarter 2026 preliminary, unaudited revenueotherapproximately $6.0 million53% sequentially–
Third quarter 2026 preliminary, unaudited net cash burn, excluding financing proceedsnon-GAAPapproximately $5.6 million29% sequential improvement–
Nine months ended September 30, 2026 preliminary, unaudited revenueotherapproximately $13.8 million–66%
Nine months ended September 30, 2026 preliminary, unaudited net cash burn, excluding financing proceedsnon-GAAPapproximately $22.2 million–8% improvement
Cash and cash equivalents as of September 30, 2026otherapproximately $37.9 million––
Cash and cash equivalents as of March 31, 2026other$40.8M––
Cash and cash equivalents as of December 31, 2025other$35.1M––
Net financing proceeds for the quarter ended September 30, 2026other$0.0 million––
Net financing proceeds for the nine months ended September 30, 2026otherapproximately $25.0 million––
Net financing proceeds for the year ended December 31, 2025other$27.3M––

Full year 2026 outlook

  • Revenueapproximately $20 to $22 million
  • NoteNet cash burn, excluding financing proceeds: approximately $26 to $28 million
  • NoteRevenue: 55% growth at the midpoint as compared to full year 2025
  • NoteNet cash burn: 10% decline at the midpoint as compared to full year 2025

What drove it

  • New and follow-on orders from health systems.
  • Expansion across hospital sites of care.
  • Adoption in office-based, wellness and longevity, and mobile settings.
  • Rollout of the Model 2 Swoop system in international markets.
  • Preliminary third-quarter revenue is expected to exceed preliminary third-quarter net cash burn for the first time.

Concerns

  • All reported third-quarter and nine-month 2026 financial information is preliminary and unaudited and remains subject to completion of quarter-end closing procedures and further financial review.
  • Actual results may differ from the preliminary estimates due to closing procedures, review adjustments and other developments.
  • The company expects to provide complete third-quarter 2026 financial results during its earnings call on November 9, 2026.
  • The company states that future financing proceeds could cause actual net change in cash and cash equivalents to differ materially from net cash burn guidance.

What to watch

  • Final third-quarter 2026 financial results expected during the November 9, 2026 earnings call.
  • Whether full-year revenue reaches the reaffirmed approximately $20 to $22 million range.
  • Whether full-year net cash burn, excluding financing proceeds, reaches the reaffirmed approximately $26 to $28 million range.
  • Progress in health systems, hospital sites of care, office-based, wellness and longevity, mobile, and international settings.
  • Cash and cash equivalents following the approximately $37.9 million preliminary September 30, 2026 balance.

Balance sheet and cash flow

  • Preliminary, unaudited cash and cash equivalents as of September 30, 2026 are expected to be approximately $37.9 million.
  • The Company did not raise any financing proceeds during the third quarter of 2026.
  • Cash and cash equivalents were $40.8 million as of March 31, 2026 and $43.5 million as of June 30, 2026.
  • Cash and cash equivalents were $37.6 million as of December 31, 2024, $21.6 million as of September 30, 2025, and $35.1 million as of December 31, 2025.
  • Net financing proceeds in the aggregate were $10.6 million for the quarter ended June 30, 2026 and $0.0 million for the quarter ended September 30, 2026.
  • Net financing proceeds in the aggregate were $8.1 million for the nine months ended September 30, 2025, and preliminary, unaudited are expected to be approximately $25.0 million for the nine months ended September 30, 2026.
  • Net financing proceeds in the aggregate were $27.3 million for the year ended December 31, 2025.

Analysis

Hyperfine reported preliminary, unaudited third-quarter revenue expected to be approximately $6.0 million, which it characterized as record revenue and 53% sequential growth. Management attributed commercial momentum to new and follow-on health-system orders, expansion across hospital sites of care, adoption in office-based, wellness and longevity, and mobile settings, plus the Model 2 Swoop rollout in international markets. No revenue by commercial vertical, geography, or product was provided.

Operating leverage was the central accompanying financial message. Preliminary third-quarter net cash burn, excluding financing proceeds, is expected to be approximately $5.6 million, a 29% sequential improvement. The company said preliminary third-quarter revenue is expected to exceed preliminary third-quarter net cash burn for the first time. For the nine months ended September 30, 2026, preliminary revenue is expected to be approximately $13.8 million, up 66%, while preliminary net cash burn is expected to be approximately $22.2 million, an 8% improvement.

Preliminary cash and cash equivalents at September 30, 2026 are expected to be approximately $37.9 million, compared with $43.5 million at June 30, 2026 and $21.6 million at September 30, 2025. The company reported no financing proceeds in the third quarter. However, aggregate net financing proceeds are preliminarily expected to be approximately $25.0 million for the nine months ended September 30, 2026, and the company identifies March 2026 debt financing among the financing sources included in its net cash burn calculation.

Management reaffirmed full-year 2026 revenue guidance of approximately $20 to $22 million and net cash burn, excluding financing proceeds, guidance of approximately $26 to $28 million. The release does not provide gross margin, operating expenses, operating income, net income, EPS, free cash flow, debt, or revenue segment detail. Investors should focus on the final third-quarter results expected on November 9, 2026, because all current-period figures are preliminary, unaudited, and subject to further review.

Management, verbatim

Our preliminary third-quarter results demonstrate that execution of our commercial strategy is driving meaningful growth. Momentum was strong across our three commercial verticals, with new and follow-on orders from health systems, expansion across hospital sites of care, adoption in office-based, wellness and longevity, and mobile settings, and the rollout of our Model 2 Swoop system in international markets.

Maria Sainz, President and Chief Executive Officer of Hyperfine, Inc.

Preliminary expected revenue of approximately $6.0 million represents a significant step up, with 53% sequential growth, while strong operating discipline is reflected in lower cash burn.

Maria Sainz, President and Chief Executive Officer of Hyperfine, Inc.

Not in the filing

stated, not guessed
  • GAAP gross profit and gross margin
  • GAAP operating expenses
  • GAAP operating income or loss
  • GAAP net income or loss
  • GAAP earnings or loss per share
  • Non-GAAP earnings or loss per share
  • Revenue by segment, product, geography, or commercial vertical
  • Prior-year third-quarter revenue
  • Prior-quarter revenue amount
  • Prior-year third-quarter net cash burn
  • Prior-year nine-month revenue amount
  • Prior-year nine-month net cash burn amount
  • Operating cash flow
  • Free cash flow
  • Debt balance
  • Share repurchases
  • Dividends
  • Prior outlook for comparison
  • Reconciliation of full-year 2026 net cash burn guidance to forward-looking net change in cash and cash equivalents

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about HYPR earnings dates

When is Hyperfine's next earnings date?
AlphAI has no date for HYPR yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.